相关实验视频

Updated: May 11, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

术后狂妄和血氨基酸β寡合体之间的关系

YoungSoon Yang¹, Ki Jin Jung², Yong Tae Kwak³

¹Department of Neurology, Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.

Scientific reports

|April 16, 2025

概括

在手术后经历了术后妄 (POD) 的老年人显示了更高的血氨基酸β寡合物水平. 这表明阿尔茨海默病生物标志物与POD之间存在潜在联系,需要进一步调查.

科学领域:

老年医学老年医学
神经学神经学
麻醉学麻醉学

背景情况:

手术后妄 (POD) 是一般麻醉后老年患者的常见并发症.
阿尔茨海默病的特点是粉样β (Aβ) 的积累.

研究的目的:

在老年手术患者中研究血氨基β寡合体水平和POD之间的关联.
探索阿尔茨海默病生物标志物与POD发生之间的关系.

主要方法:

在患有POD和没有POD的患者中比较血氨基酸β oligomer水平 (MDS-OAβ).
包括104名参与者,最终分析31个匹配对 (POD与没有POD).
使用韩国痴呆症评分尺度-98 (K-DRS-98) 评估痴呆症的严重程度.

主要成果:

与对照组相比,POD患者的血MDS-OAβ水平显著更高.
在POD组中观察到MDS-OAβ水平和K-DRS-98得分之间的正相关性.
在这个队列中,粉样蛋白寡合体水平升高与POD有关.

结论:

研究结果表明,在接受手术的老年人中,血氨基酸寡合体水平升高和POD之间存在联系.
需要进一步的前性研究来确定因果关系.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.粉样蛋白β oligomer 是一种粉样蛋白β oligomer.这就是MDS-Oaβ.手术后妄症术后妄症

更多相关视频

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...